Biogen Inc BIIB shares are trading lower by $2.00 at $282.70 in Tuesday's session.
The stock in the red despite posting a Q2 EPS beat of 63 cents along with a $17 million beat for sales. The company significantly raised FY 2017 EPS and sales guidance.
After a higher open, Biogen continued in that direction before finally peaking at $291.91 and reversing course. The ensuing decline has found support in a familiar area. Over its previous five sessions, it has bottomed in the $280.00 handle, between $280.01 and $280.75 and today's low stands at $280.24 as of 12:30 p.m. EST.
The rebound off that low peaked at $287.56 and is now drifting back towards the low for the session.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.